Related Experiment Videos
Interferon-beta activates multiple signaling cascades in primary human microglia
Mee-Ohk Kim1, Qiusheng Si, Jian Nian Zhou
1Department of Pathology, Albert Einstein College of Medicine, New York 10461, USA.
Abstract:
Microglia, the resident brain macrophages, are the principal cells involved in the regulation of inflammatory and antimicrobial responses in the CNS. Interferon-beta (IFNbeta) is an antiviral cytokine induced by viral infection or following non-specific inflammatory challenges of the CNS. Because of the well-known anti-inflammatory properties of IFNbeta, it is also used to treat multiple sclerosis, an inflammatory CNS disease. Despite the importance of IFNbeta signaling in CNS cells, little has been studied, particularly in microglia. In this report, we investigated the molecular mechanisms underlying IFNbeta-induced beta-chemokine expression in primary human fetal microglia. Multiple signaling cascades are activated in microglia by IFNbeta, including nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1) and Jak/Stat. IFNbeta induced IkappaBalpha degradation and NF-kappaB (p65:p50) DNA binding. Inhibition of NF-kappaB by either adenoviral transduction of a super repressor IkappaBalpha, or an antioxidant inhibitor of NF-kappaB reduced expression of the beta-chemokines, regulated upon activation, normal T-cell expressed and secreted (RANTES) and macrophage inflammatory protein (MIP)-1beta. IFNbeta also induced phosphorylation of extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase, and the MAP kinase kinase 1 (MEK1) inhibitor PD98059 dose-dependently inhibited beta-chemokine mRNA and protein expression. PD98059 did not inhibit NF-kappaB binding, demonstrating that ERK was not responsible for NF-kappaB activation. Two downstream targets of ERK were identified in microglia: AP-1 and Stat1. IFNbeta induced AP-1 nuclear binding activity in microglia and this was suppressed by PD98059. Additionally, IFNbeta induced Stat1 phosphorylation at both tyrosine 701 (Y701) and serine 727 (S727) residues. S727 phosphorylation of Stat1, which is known to be required for maximal transcriptional activation, was inhibited by PD98059. Our results demonstrating multiple signaling cascades initiated by IFNbeta in primary human microglia are novel and have implications for inflammatory and infectious diseases of the CNS.
Insights
Interferon-beta (IFNbeta) activates multiple signaling pathways in microglia, including NF-kappaB and ERK, to induce beta-chemokine expression. These findings offer insights into CNS inflammatory and infectious diseases.
Area of Science:
- Neuroimmunology
- Molecular Biology
- Cellular Signaling
Background:
- Microglia are key immune cells in the central nervous system (CNS).
- Interferon-beta (IFNbeta) has anti-inflammatory properties and is used to treat multiple sclerosis.
- IFNbeta signaling in microglia is not well understood.
Purpose of the Study:
- To investigate the molecular mechanisms of IFNbeta-induced beta-chemokine expression in primary human microglia.
- To identify the signaling cascades activated by IFNbeta in microglia.
Main Methods:
- Primary human fetal microglia were treated with IFNbeta.
- NF-kappaB activation was assessed via IkappaBalpha degradation and DNA binding.
- ERK activation and downstream targets (AP-1, Stat1) were analyzed.
- Specific inhibitors (super repressor IkappaBalpha, PD98059) were used to block signaling pathways.
Main Results:
- IFNbeta induced NF-kappaB activation, leading to increased RANTES and MIP-1beta expression.
- Inhibition of NF-kappaB reduced beta-chemokine expression.
- IFNbeta activated the ERK pathway, which was essential for beta-chemokine expression.
- ERK signaling influenced AP-1 activity and Stat1 phosphorylation (S727).
Conclusions:
- IFNbeta activates multiple, distinct signaling cascades (NF-kappaB, ERK) in primary human microglia.
- Both NF-kappaB and ERK pathways contribute to IFNbeta-induced beta-chemokine expression.
- These findings enhance understanding of microglial responses in CNS inflammatory and infectious conditions.